Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril

To assess whether timing of administration can influence the antihypertensive effect of quinapril, 18 patients with hypertension were studied with noninvasive ambulatory blood pressure monitoring. Quinapril, 20 mg, was given at 8 AM or 10 PM for 4 weeks in a double-blind crossover fashion. To study...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 52; no. 4; p. 378
Main Authors Palatini, P, Racioppa, A, Raule, G, Zaninotto, M, Penzo, M, Pessina, A C
Format Journal Article
LanguageEnglish
Published United States 01.10.1992
Subjects
Online AccessGet more information

Cover

Loading…
Abstract To assess whether timing of administration can influence the antihypertensive effect of quinapril, 18 patients with hypertension were studied with noninvasive ambulatory blood pressure monitoring. Quinapril, 20 mg, was given at 8 AM or 10 PM for 4 weeks in a double-blind crossover fashion. To study the pattern of angiotensin converting enzyme (ACE) inhibition with the two treatment regimens, plasma ACE activity was measured in seven subjects 2, 4, 8, 12 and 24 hours after quinapril administration. The 24-hour blood pressure profiles showed a more sustained antihypertensive action with the evening administration of quinapril compared with the morning administration of quinapril; as with the morning administration, a partial loss of effectiveness was observed during nighttime hours. Measurement of ACE activity showed that evening administration caused a less pronounced but a more sustained decline of plasma ACE. These findings show that 20 mg quinapril given once daily is effective in lowering blood pressure levels throughout a 24-hour period. The evening administration seems to be preferable because it causes a more favorable modulation of ACE inhibition and therefore determines a more homogeneous 24-hour blood pressure control.
AbstractList To assess whether timing of administration can influence the antihypertensive effect of quinapril, 18 patients with hypertension were studied with noninvasive ambulatory blood pressure monitoring. Quinapril, 20 mg, was given at 8 AM or 10 PM for 4 weeks in a double-blind crossover fashion. To study the pattern of angiotensin converting enzyme (ACE) inhibition with the two treatment regimens, plasma ACE activity was measured in seven subjects 2, 4, 8, 12 and 24 hours after quinapril administration. The 24-hour blood pressure profiles showed a more sustained antihypertensive action with the evening administration of quinapril compared with the morning administration of quinapril; as with the morning administration, a partial loss of effectiveness was observed during nighttime hours. Measurement of ACE activity showed that evening administration caused a less pronounced but a more sustained decline of plasma ACE. These findings show that 20 mg quinapril given once daily is effective in lowering blood pressure levels throughout a 24-hour period. The evening administration seems to be preferable because it causes a more favorable modulation of ACE inhibition and therefore determines a more homogeneous 24-hour blood pressure control.
Author Raule, G
Penzo, M
Palatini, P
Zaninotto, M
Pessina, A C
Racioppa, A
Author_xml – sequence: 1
  givenname: P
  surname: Palatini
  fullname: Palatini, P
  organization: Clinica Medica 1, University of Padova, Italy
– sequence: 2
  givenname: A
  surname: Racioppa
  fullname: Racioppa, A
– sequence: 3
  givenname: G
  surname: Raule
  fullname: Raule, G
– sequence: 4
  givenname: M
  surname: Zaninotto
  fullname: Zaninotto, M
– sequence: 5
  givenname: M
  surname: Penzo
  fullname: Penzo, M
– sequence: 6
  givenname: A C
  surname: Pessina
  fullname: Pessina, A C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/1330398$$D View this record in MEDLINE/PubMed
BookMark eNo9j0trwzAQhHVISZO0xx4L-gN29XIsHYNJHxDopT2HtSQ3W2zZtZVA_n3VNhQW5ptl2GGXZBb64Am54yznTOoH2w4x58aInBd6RhaMMZMZIdfXZDlNn8kqo_WczLmUTBq9IMdt03gbad_QiB2Gjx8ClwinOELEPtA08eDp0MLUAd1UW4rhgDXGfjxTsBFPGBME9xuDEPFwHvwYfZjw5Kn_b_g6YoBhxPaGXDXQTv72oivy_rh9q56z3evTS7XZZVZJqbNaqdo4Cb4wphTKWVcz1oBdA5dWlFw4rawVyTtVeKG0F1CCEy5t10XZiBW5_7s7HOvOu33q7mA87y_vi28_SV8-
CitedBy_id crossref_primary_10_1097_01_mnh_0000174144_07174_74
crossref_primary_10_1081_CBI_120037772
crossref_primary_10_1146_annurev_pharmtox_010909_105621
crossref_primary_10_1016_S1889_1837_04_71485_3
crossref_primary_10_1586_14779072_5_3_463
crossref_primary_10_1016_S0733_8651_18_30023_7
crossref_primary_10_1097_00126097_200208000_00001
crossref_primary_10_1111_j_1749_6632_1996_tb26720_x
crossref_primary_10_1155_2013_490705
crossref_primary_10_1016_0011_393X_95_85074_0
crossref_primary_10_1111_j_1749_6632_1996_tb26722_x
crossref_primary_10_1161_01_HYP_0000084855_32823_DA
crossref_primary_10_1177_1060028014563535
crossref_primary_10_1038_ajh_2010_217
crossref_primary_10_1097_01_HDX_0000074436_09658_3b
crossref_primary_10_1002_14651858_CD004184_pub2
crossref_primary_10_1002_14651858_CD004184_pub3
crossref_primary_10_1016_S0531_5131_03_00103_1
crossref_primary_10_1111_j_1742_1241_2008_01871_x
crossref_primary_10_1038_sj_ki_5002130
crossref_primary_10_1111_j_1751_7117_2001_tb00238_x
crossref_primary_10_1007_s11906_999_0040_7
crossref_primary_10_1097_01_hjh_0000183121_69585_f1
crossref_primary_10_1586_14779072_5_3_375
crossref_primary_10_1053_sper_2000_8595
crossref_primary_10_3390_j4010005
crossref_primary_10_1111_jch_12238
crossref_primary_10_1254_jjp_87_86
crossref_primary_10_2174_1389450120666190527114529
crossref_primary_10_2165_00129784_200505010_00002
crossref_primary_10_1081_CEH_120028546
crossref_primary_10_1097_HJH_0000000000002532
crossref_primary_10_1002_j_1552_4604_1996_tb04250_x
crossref_primary_10_1007_s11906_000_0039_6
crossref_primary_10_1097_HJH_0000000000000397
crossref_primary_10_1097_MBP_0b013e32833c7308
crossref_primary_10_1016_j_smrv_2021_101454
crossref_primary_10_3109_07420529808998681
crossref_primary_10_1124_jpet_105_092080
crossref_primary_10_1007_s11096_009_9362_4
crossref_primary_10_1007_s11906_018_0897_4
crossref_primary_10_3109_08037059509077587
crossref_primary_10_3390_biom11060868
crossref_primary_10_1016_j_ijcard_2005_03_046
crossref_primary_10_1016_S0304_4858_06_74515_2
crossref_primary_10_1016_S1062_0303_05_80017_2
crossref_primary_10_1007_s40292_013_0013_4
crossref_primary_10_1016_S0002_9149_99_80104_0
crossref_primary_10_3904_kjim_2023_304
crossref_primary_10_1017_S1092852900008026
crossref_primary_10_1111_j_1542_4758_2009_00392_x
crossref_primary_10_3109_07420528_2012_709448
crossref_primary_10_1080_17425255_2020_1825681
crossref_primary_10_1097_00041552_200409000_00004
crossref_primary_10_1097_XCE_0000000000000103
crossref_primary_10_1016_j_jvs_2004_04_019
crossref_primary_10_1016_j_addr_2006_09_021
crossref_primary_10_1002_cpt_2073
crossref_primary_10_2147_tcrm_2007_3_1_119
crossref_primary_10_1007_s11906_015_0537_1
crossref_primary_10_1097_00004872_199715020_00012
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1038/clpt.1992.158
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 1330398
Genre Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
--K
-Q-
.55
.GJ
0R~
1B1
1CY
1OB
1OC
29B
33P
354
36B
39C
3O-
4.4
52O
53G
5GY
5RE
6J9
70F
8F7
AAESR
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQOH
AAQQT
AAWTL
AAYCA
AAYOK
AAZKR
ABCUV
ABJNI
ABLJU
ABQWH
ACBNA
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACPOU
ACRPL
ACXQS
ACYXJ
ADBBV
ADBTR
ADKYN
ADNMO
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AENEX
AEQDE
AEUYR
AFBPY
AFFNX
AFFPM
AHBTC
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMYDB
ASPBG
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BMXJE
BRXPI
C45
CAG
CGR
COF
CS3
CUY
CVF
DCZOG
DPXWK
DU5
EBS
ECM
EE.
EIF
EJD
EMOBN
F5P
GODZA
GWYGA
HGLYW
IH2
IHE
J5H
L7B
LATKE
LEEKS
LITHE
LOXES
LSO
LUTES
LYRES
M41
MEWTI
N4W
N9A
NPM
NQ-
O9-
OPC
OVD
P2P
P2W
PALCI
PKN
RIG
RIWAO
RJQFR
RNTTT
ROL
RPZ
SAMSI
SEW
SJN
SUPJJ
TEORI
TWZ
UHS
VH1
WBKPD
WH7
WOHZO
WXSBR
WYJ
X7M
Y6R
YCJ
YFH
YOC
YXB
ZGI
ZXP
ZZTAW
ID FETCH-LOGICAL-c4338-b44b9d3ae599724dcdb00fac6a13c2712d84cc2c6ad45e248e2a7ad2d4cc657f2
ISSN 0009-9236
IngestDate Wed Feb 19 02:36:59 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4338-b44b9d3ae599724dcdb00fac6a13c2712d84cc2c6ad45e248e2a7ad2d4cc657f2
PMID 1330398
ParticipantIDs pubmed_primary_1330398
PublicationCentury 1900
PublicationDate October 1992
PublicationDateYYYYMMDD 1992-10-01
PublicationDate_xml – month: 10
  year: 1992
  text: October 1992
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical pharmacology and therapeutics
PublicationTitleAlternate Clin Pharmacol Ther
PublicationYear 1992
SSID ssj0004988
Score 1.7128274
Snippet To assess whether timing of administration can influence the antihypertensive effect of quinapril, 18 patients with hypertension were studied with noninvasive...
SourceID pubmed
SourceType Index Database
StartPage 378
SubjectTerms Adult
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Blood Pressure - drug effects
Circadian Rhythm - physiology
Double-Blind Method
Drug Administration Schedule
Female
Heart Rate - drug effects
Humans
Hypertension - drug therapy
Hypertension - enzymology
Isoquinolines - administration & dosage
Male
Middle Aged
Peptidyl-Dipeptidase A - blood
Peptidyl-Dipeptidase A - drug effects
Quinapril
Tetrahydroisoquinolines
Title Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril
URI https://www.ncbi.nlm.nih.gov/pubmed/1330398
Volume 52
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA5TEXwRr3gnD-KLq65puraPIpMhKEMmDF8kzUUL2lXdHvRv-Ic9adLLpuIFRsmSknb5vp3kJOeC0D6BVRvMkqETB0o6lEKJcRo5MDlrV0zS8rneh7y4bHev6fnAHzQa7zWrpfEoPuJvX_qV_AdVqANctZfsH5AtO4UKKAO-cAWE4forjG3oYX3Mr5Nz3ZlD_Xo0XHsWoJNFvzyyw5PTzmGS3idxkp-ta6eGPHdEYUYJw5zcg2b6XNi1y_IJT-MkZdmztcgoYhsUfpVZFQG77K3w6ypX7T2mDe_yHFKVW9kV48kwy9jEvuoVGxsz5zLz1w1Lk3Q4ypM-2R1cYZ33SGn1VsnfyIElZbsuf31S4xmtCVPPJPf5JORNSHf-kI20ryU5cv2J-wCj7DFHHPTvlhf93DgVcdu2zKAZUD10LlW9AVS42kZhWCTn0z_Ehm2FVzqeeKEFNG-7mdJX8nVLfwktWoUDnxj2LKOGTFfQQc_g9drE_RpQTXyAezUkV9HYUAwPFTYU06VJimH4ANrYUAwDxXBFMVxQDAMp8tumKYZl-YSSYmvo-qzTP-06NlOHw6kHM2ZMaRwJj0lf-2FTwQVIc8V4m7keJ4FLREg5J_BdUF8SGkrCAiaIgNq2HyiyjmbTYSo3EHZ9xUBsqBblHuWUMsKEG6pYuC0eSBVtonUznLeZCcdya8d567uGbbRQcXEHzSn498tdWEqO4r0c3A_WHnkv
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+timing+of+administration+on+the+plasma+ACE+inhibitory+activity+and+the+antihypertensive+effect+of+quinapril&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Palatini%2C+P&rft.au=Racioppa%2C+A&rft.au=Raule%2C+G&rft.au=Zaninotto%2C+M&rft.date=1992-10-01&rft.issn=0009-9236&rft.volume=52&rft.issue=4&rft.spage=378&rft_id=info:doi/10.1038%2Fclpt.1992.158&rft_id=info%3Apmid%2F1330398&rft_id=info%3Apmid%2F1330398&rft.externalDocID=1330398
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon